- Conditions
- Premature Ventricular Contractions
- Interventions
- MIBG nuclear scan
- Other
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 27
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Congestive Heart Failure
- Interventions
- 123 iodine metaiodobenzylguanidine
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Post-menopause
- Interventions
- Study Procedures
- Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 45 Years and older · Female only
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia
- Conditions
- Ventricular Tachycardia, Arrhythmia
- Interventions
- 123I-metaiodobenzylguanidine
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2019
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma, Refractory Ganglioneuroblastoma, Refractory Neuroblastoma
- Interventions
- Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Dinutuximab, Echocardiography Test, FDG-Positron Emission Tomography, Iberdomide, Magnetic Resonance Imaging, Multigated Acquisition Scan, Nuclear Radiology Imaging Procedure, Sargramostim, Topotecan
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2029
- U.S. locations
- 1
- States / cities
- Oakland, California
- Conditions
- Heart Failure, Systolic
- Interventions
- Yoga training
- Behavioral
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Thyroid Cancer
- Interventions
- 131 I-iodine (131-I), 124 I-iodine (124-I)
- Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Neuroblastoma
- Interventions
- Hu3F8 With GM-CSF
- Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 1 Year and older
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Heart Failure
- Interventions
- Iobenguane I -123 Injection, Implantable Cardioverter Defibrillator, Thyroid blocking
- Drug · Device
- Lead sponsor
- GE Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 395 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Bakersfield, California • La Mesa, California + 24 more
- Conditions
- Heart Failure, Congestive
- Interventions
- 123I-mIBG (meta-iodobenzylguanidine)
- Drug
- Lead sponsor
- GE Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 515 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Neuroendocrine Tumors, Heart Failure
- Interventions
- no carrier added metaiodobenzylguanidine
- Drug
- Lead sponsor
- Bennett Chin
- Other
- Eligibility
- 21 Years to 85 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Pheochromocytoma
- Interventions
- [131]I-MIBG, 6-[18F]Fluorodopamine, [123]I-MIBG
- Drug
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2007
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Microvascular Coronary Dysfunction
- Interventions
- Mental Stress Testing, Peripheral Arterial Tonometry (PAT) Testing, Heart Rate Variability (HRV), RESPeRATE Breathing Trial, SPECT cardiac scan with 123I-mIBG and Myoview
- Behavioral · Other · Procedure
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 105 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2024
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Neuroblastoma
- Interventions
- Iobenguane I 123 Injection
- Drug
- Lead sponsor
- GE Healthcare
- Industry
- Eligibility
- Not listed
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Congestive Heart Failure
- Interventions
- I-123 mIBG
- Drug
- Lead sponsor
- GE Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 471 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Ganglioneuroblastoma, Nodular, Neuroblastoma
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Dinutuximab, FDG-Positron Emission Tomography, Iobenguane I-123, Irinotecan, Isotretinoin, Magnetic Resonance Imaging, Multigated Acquisition Scan, Sargramostim, Temozolomide
- Procedure · Biological · Radiation + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 30 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 70
- States / cities
- Mesa, Arizona • Little Rock, Arkansas • Downey, California + 58 more
- Conditions
- Stress Induced Cardiomyopathy
- Interventions
- I-123 radiolabeled metaiodobenzylguanidine cardiac imaging
- Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- REM Sleep Behavior Disorder, Pre-motor Parkinson's Disease, Symptomatic Parkinson Disease
- Interventions
- Terazosin
- Drug
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Lewy Body Disease, Dementia, Parkinsonism, Mild Cognitive Impairment, REM Sleep Behavior Disorder
- Interventions
- meta-iodobenzylguanidine (MIBG) (123I), 123I-MIBG scintigraphy
- Drug · Diagnostic Test
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 40 Years to 90 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Heart Failure (HF), Ventricular Dysfunction, Left
- Interventions
- AdreView (Iobenguane I 123 Injection)
- Drug
- Lead sponsor
- GE Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Neuroendocrine Tumors
- Interventions
- 3-[18F]Fluoro-para-hydroxyphenethylguanidine, [123I] metaiodobenzylguanidine, Positron emission tomography/computed tomography scan, Planar scintigraphy scan, Single photon emission computed tomography/computed tomography scan
- Drug · Diagnostic Test
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Heart Failure, Cardiomyopathy
- Interventions
- AdreView, Single Photon Emission Computed Tomography
- Drug · Other
- Lead sponsor
- Timothy M. Bateman
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Pheochromocytoma, Neuroblastoma
- Interventions
- 123I-mIBG (meta-iodobenzylguanidine)
- Drug
- Lead sponsor
- GE Healthcare
- Industry
- Eligibility
- Not listed
- Enrollment
- 251 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Neuroendocrine Tumor
- Interventions
- Standard of care diagnostic MIBG scan for neuroendocrine tumor diagnosis.
- Other
- Lead sponsor
- Nuclear Medicine Consultants, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 1
- States / cities
- Kenner, Louisiana